EVLO (Evelo Biosciences) EBITDA Margin %: 0.00% (As of Sep. 2023)

What is Evelo Biosciences EBITDA Margin %?

Evelo Biosciences EVLO -99.00% EBITDA Margin % is 0.00% as of Sep. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evelo Biosciences's EBITDA for the three months ended in Sep. 2023 was $-11.05 Mil. Evelo Biosciences's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Evelo Biosciences's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.

Evelo Biosciences (OTCPK:EVLO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Evelo Biosciences EBITDA Margin % Related Terms

Evelo Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences EBITDA Margin % Chart

Evelo Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

0.00

Evelo Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

EVLO vs IMNN, EDSA, TMBR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Evelo Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's EBITDA Margin % falls into.

Save Embed

Evelo Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Evelo Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-106.865	/	0
	=	%

Evelo Biosciences's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-11.05	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Evelo Biosciences (EVLO) has a EBITDA Margin % of 0.00% as of Sep. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evelo Biosciences and its competitors.

Is Evelo Biosciences' EBITDA Margin % too high?

Evelo Biosciences' current EBITDA Margin % is 0.00%.

How does Evelo Biosciences' EBITDA Margin % compare to IMNN and EDSA?

Evelo Biosciences' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evelo Biosciences stock overvalued right now?

Evelo Biosciences (EVLO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current EBITDA Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies IMNN EDSA TMBR EIGR SIGY GRTX CMRA ONVO VYNE ARAV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 620 Memorial Drive, Cambridge, MA, USA, 02139

Website https://www.evelobio.com

Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.